Omega-3 News

Stay updated with the latest research, trends, and market news regarding Omega-3. Curated daily for quality and relevance.

3/11/2026defenseworld

Head to Head Analysis: Zealand Pharma A/S (OTCMKTS:ZLDPF) versus Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN – Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Earnings and Valuation This table compares Amarin and [...]

Read Full Synopsis
3/11/2026news_market_us

EPA And DHA Market Reaching USD 4.0B

Overview New York, NY – March 11, 2026 – The global EPA and DHA market is projected to reach around USD 4.0 billion by 2034, rising from USD 2.0 billion in 2024, with steady growth driven by increasing consumer focus on health and preventive nutrition. North America currently represents a significant share of the market, accounting [...]The post EPA And DHA Market Reaching USD 4.0B appeared first on Market.us News.

Read Full Synopsis
3/10/2026sciencedaily

Omega-3 fish oil supplements cut heart attacks and strokes by 43% in dialysis patients

A major international trial has found that daily fish oil supplements significantly reduced life-threatening cardiovascular events in dialysis patients. People who took four grams per day had a 43% lower risk of heart attack, stroke, cardiac death, or vascular-related amputations compared with those on placebo. The findings stand out because few treatments have successfully lowered heart risk in this high-risk group.

Read Full Synopsis
1/9/2026globenewswire

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin’s VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.

Read Full Synopsis